Potential future frontline induction therapy for common nodal PTCL. Future treatment of common PTCLs should recognize numerous distinct entities and appropriately incorporate novel agents to optimize the therapy for each individual. Alternative treatment approaches may be appropriate for subtypes associated with poor prognosis such as TP53-mutated or CDKN2A-deleted PTCL, NOS, TP63-rearranged ALCL, and DNMT3A–mutated TFH lymphomas. Hypothetical strategies are shown that integrate targeted agents based on biologic features or known drug sensitivity for disease subtypes.